The Conversation (0)
Opsens announced the conversion of the US$2 million debenture held by Zeon Medical, their Japanese partner.
Opsens (TSX:OPS; OTCQX:OPSSF) announced the conversion of the US$2 million debenture held by Zeon Medical, their Japanese partner.
As quoted in the press release:
Zeon Medical has been a client of Opsens since 2004. In 2012, Opsens granted Zeon Medical the exclusive distribution rights for its products designed to measure Fractional Flow Reserve (“FFR”) in Japan, Korea and Taiwan.
Today, Opsens announced that the aggregate principal amount under the debenture and the accrued interest had been fully converted into common shares of the Company.
Dr. Noboru Yanagida, President of Zeon Medical, said: “we are delighted to become a shareholder of Opsens. We appreciate the business partnership we have developed and expect to continue to grow this relationship for the benefit of our two companies.”
Source: www.newswire.ca
